Layered Nanoparticle Platform Could Expand Targeted Radioisotope Cancer Therapies
Scientists have developed a specialised nanoplatelet that rapidly captures and strongly retains radioisotopes, potentially creating a versatile platform for targeted cancer imaging, radionuclide therapy and theranostic applications.
Theranostics | 19/08/2026 | By News Bureau
Harbour BioMed Signs Strategic Collaboration with Lannacheng on Radionuclide Drug Conjugates
Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation radionuclide drug conjugates, combining both companies’ resources and expertise to accelerate innovation in targeted radiopharmaceutical therapies.
Theranostics | 30/12/2025 | By News Bureau | 169
Nucleus RadioPharma Receives Series A Extension Funding from AstraZeneca
Nucleus RadioPharma has closed its Series A extension round with new investor AstraZeneca.
Theranostics | 06/06/2024 | By Aishwarya | 865
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy